1-866-598-7166

New Targeted Radiotherapy (FPI-2068) for Advanced or Returning Kidney Cancer

Trial ID: NCT06147037
Kidney Cancer Type: Any


Background:

This study is testing a new targeted radiotherapy called FPI-2068. It is designed to bring a tiny amount of radiation directly to cancer cells while avoiding most healthy tissues.

FPI-2068 works like a “smart delivery system.” It uses a molecule that finds and attaches to certain proteins on cancer cells, carrying a radioactive particle (Actinium-225) straight to them. Once inside, the radiation helps destroy the cancer cell from within.

Researchers hope this new approach will offer a more precise and effective way to treat advanced cancers—including kidney cancer—while reducing side effects compared to traditional radiation.


The Trial:

The goal of this study is to find the safest and most effective dose of the new targeted radiotherapy FPI-2068 for people with advanced or returning cancers, including kidney cancer.

Participants will be placed into two main study groups:

  • Part A: Patients will receive a fixed dose of FPI-2068 together with different doses of a helper drug called FPI-2053 to find the best combination.
  • Part B: Once the best FPI-2053 dose is identified, new patients will receive increasing doses of FPI-2068 to determine the safest and most effective amount for future studies.

This trial is not “blinded”, which means both you and your doctor will know which treatment you are receiving.

 

Basic Eligibility:

  • The cancer has spread to other parts of the body, come back after treatment, or cannot be removed by surgery.
  • The disease has continued to grow or worsen despite previous treatment, and there are no standard treatment options left.

 

Additional eligibility criteria will apply. Please speak to your doctor.

Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentreCross Cancer Institute Principal InvestigatorMichael Sawyer LocationEdmonton, AB Trial StatusNot yet recruiting
Hospital / Cancer CentreQueen Elizabeth II Health Sciences Centre Principal InvestigatorRavi Ramjeesingh LocationHalifax, NS Trial StatusNot yet recruiting
Hospital / Cancer CentreCHUM Principal InvestigatorDaniel Juneau LocationMontreal, QC Trial StatusRecruiting
Hospital / Cancer CentreCIUSSS de l’Estrie - CHUS Principal InvestigatorMichel Pavic LocationSherbrooke, QC Trial StatusRecruiting
Kidney Cancer Canada